Virax Biolabs Signs Agreement with Europa Biosite to Commercialize Immuneselect
Virax Biolabs enters distribution agreement with Europa Biosite to commercialize ImmuneSelect in UK & Ireland
Overview
Virax Biolabs Group Limited, an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced that it has entered into a distribution agreement with Europa Biosite to commercialize the company's ImmuneSelect Research Use portfolio in the United Kingdom and Ireland through its wholly owned subsidiary Cambridge Bioscience.
Words from the CEO: Virax Biolabs
"ImmuneSelect is an important suite of profiling solutions for assessing adaptive immunity and we are pleased to partner with Europa Biosite, a leader in life science distribution across Europe," said James Foster, CEO of Virax Biolabs.
"We believe this partnership will meaningfully expand our commercial footprint in the UK and Ireland and make ImmuneSelect accessible to researchers and pharmaceutical companies as they work to better understand the role of T cell response and immune status."
Statement from Europa Biosite
"We are happy to partner with innovative companies like Virax Biolabs," commented Martijn Blommaart, director of supplier development at Europa Biosite.
"We look forward to leveraging our commercial infrastructure to quickly deliver and provide local technical support to ensure that ImmuneSelect is available in the UK & Ireland"
About ImmuneSelect
ImmuneSelect is the company's portfolio of research products dedicated to investigating adaptive immunity.
Products within the ImmuneSelect brand are for research and investigational use only and are not intended to be used as a diagnostics tool.
The European supplier: Europa Biosite
Europa Biosite is a European supplier of life science products and services, composed of six leading distribution companies: Biomol in Germany, Cambridge Bioscience in the UK and Ireland, LubioScience in Switzerland, Nordic Biosite in the Nordics and Baltics, Sanbio in Benelux and Szabo-Scandic in Austria.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases.
Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!